Beschreibung:
<jats:p>Aim: To understand how remote Certified Diabetes Care and Education Specialists (CDCES) helped adults with type 1 diabetes (T1D) transition from provider in-person to tele-visits.</jats:p>
<jats:p>Methods: Adults with T1D were referred to remote CDCES to fulfill needs from 4/16/2020 - 8/14/2020. Pertinent information from the EMR was provided to the CDCES who were not previously known to the patients. A summary of the remote CDCES encounter was communicated to the provider. Data analysis used t-tests to assess differences in means and Pearson correlation coefficients to assess relationship between the number of encounters and insurance and age. SPSS v. 27 was used.</jats:p>
<jats:p>Results: Adults (n=1089) with T1D [mean age 46 (range 18-90 yrs); 50% female; 20% Medicaid, 23% Medicare, 54% private coverage; mean A1c 8.4% (range 4.6 to &gt;14.0%); 52% pump and 61% CGM users], had 1662 encounters with remote CDCES. Of those referred, 232 (21%) could not be reached or did not receive education/support. Older age was associated with more encounters (r=0.126, p&lt;0.001) as was coverage with Medicare (mean 1.9) vs. private insurance (mean 1.3; p&lt;0.001) vs. Medicaid (mean 1.6; NS). A1c was negatively correlated with age (r=-0.195, p&lt;0.001). During remote encounters the most frequently discussed topics were CGM (64%), insulin pumps (48%), tele-visit preparation (37%) and hypoglycemia (24%); device download training (46%) and CGM education/data review (58%) was provided to participants. Lack of access to a computer, tablet, smartphone or internet was seen in 14%; mean age of those without vs. with access was 51 vs. 45 yrs (p&lt;0.001).</jats:p>
<jats:p>Conclusions: Most remote CDCES encounters in adults with T1D were successfully completed, assisting the majority with CGM education/data review and nearly half with device download training in preparation for their provider tele-visit. Older adults and those with Medicare required more encounters to fulfill needs. Future study could assess whether remote encounters result in improved glycemic control or quality of life.</jats:p>
<jats:sec>
<jats:title>Disclosure</jats:title>
<jats:p>M. Greenfield: None. D. L. Stuber: None. D. Stegman-barber: None. K. Kemmis: None. B. A. Wells: None. T. S. Mcarthur: None. B. Matthews: None. C. P. Morley: None. R. S. Weinstock: Research Support; Self; Boehringer Ingelheim International GmbH, Diasome Pharmaceuticals, Inc., Eli Lilly and Company, Insulet Corporation, Kowa Research Institute, Inc., Medtronic, Tolerion, Inc.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Funding</jats:title>
<jats:p>The Leona M. and Harry B. Helmsley Charitable Trust; T1D Exchange QI Learning Collaborative</jats:p>
</jats:sec>